Human Pulmonary Artery Endothelial Cells: HPAEC (A). HPAEC immunolabeled for CD31/PECAM (Cat# CB13678); nuclei stained with PI (red) (B). HPAEC transfected with GFP plasmid DNA using the Cytofect™ Endothelial Cell Transfection Kit (C,D).
Human Pulmonary Artery Endothelial Cells: HPAEC
Description
Human Pulmonary Artery Endothelial Cells (HPAEC) provide an excellent model system to study many aspects of cardiovascular function and disease, including diabetes-associated complications, mechanisms of endothelial dysfunction caused by environment, oxidative stress, hypoxia and inflammation, as well as mode of action of various natural compounds and drug candidates.
Note that several publications describe the differences between endothelial cells from different vascular beds and between macro- and micro-vascular cells from the same organ, highlighting the importance of confirming any new findings on cell lots obtained from several different origins. Cell Applications, Inc. offers the widest variety of endothelial cells, and is well equipped to meet this need.
HPAEC from Cell Applications have been used to investigate or demonstrate
- Vasculoprotective effects of propofol, demonstrating its potential for treating pulmonary arterial hypertension
- Hits from a high-throughput screening assay and discover anziaic acid inhibits bacterial activity
- Endothelin-1 is released by endothelial cells during acute crisis in sickle cell anemia, increases vascular constriction
- Pollutant particles cause vascular dysfunction by up-regulating clotting-related genes
- Central role of AMP-activated protein kinase in normal endothelial barrier function can be disrupted, causing endothelial hyperpermeability and lung injury
- Anti-inflammatory and cardioprotective effects of resveratrol
- cGMP prevents oxidant-induced damage to the endothelial barrier function
- Radiation causes endothelial cell senescence due to up-regulation of proliferative signaling in the presence of cell cycle arrest
- Vanadium exposure causes pulmonary vasoconstriction mediated in part by the inhibition of endothelial NO production
- Cytotoxic effects of a novel pore-forming protein, proposed as an anti-tumor agent
- Effects of Bone Morphogenic Protein-4, helping to explain why its upregulation leads to atherosclerosis and hypertension
- Macro-vascular pulmonary endothelial cells accumulate HIF-1 under hypoxic conditions
- Transportation of bioactive lipids and its silencing by siRNA
Details
| Tissue | Normal healthy human pulmonary artery | |
|---|---|---|
| QC | No bacteria, yeast, fungi, mycoplasma, virus | |
| Character | VIII-related Ag expression, DiI-Ac-LDL uptake | |
| Bioassay | Attach, spread, proliferate in Growth Med | |
| Cryovial | 500,000 HPAEC (2nd passage) frozen in Basal Medium w/ 10% FBS, 10% DMSO | |
| Kit | Cryovial frozen HPAEC (302-05a), Growth Medium (211-500), Subculture Rgnt Kit (090K) | |
| Proliferating | Shipped in Gr Med, 3rd psg (flasks or plates) | |
| Doublings | At least 15 | |
| Applications | Laboratory research use only (RUO). Not for human, clinical, diagnostic or veterinary use. |
Resources
FAQs
Need More Help?
Visit our comprehensive FAQ page for detailed answers to common questions.
Need More Help?
Visit our comprehensive FAQ page for detailed answers to common questions.
Primary Cell FAQs
Powered by Bioz